What Dafor Treats: Main Uses and Benefits

Dafor (Amlodipine) is commonly used across key therapeutic domains to support long-term cardiovascular stability and manage associated symptomatic burden. The medication is applied for conditions requiring supportive relief from systemic vascular strain and episodes of chest discomfort.

The medication is relevant for easing symptoms in conditions such as chronic high blood pressure (hypertension), chronic stable angina, and vasospastic (Prinzmetal's) angina. It assists patients primarily by helping to reduce the daily, chronic strain related to high pressure on the circulatory system and by addressing recurrent chest discomfort associated with reduced heart oxygen supply.

This support helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

“This application is relevant for easing symptoms that are linked to the temporary narrowing of coronary vessels, which often occur with Prinzmetal's angina.”

---

Quick Fact: Relief for Vascular Strain
Symptom Axis Targeted	Persistently elevated blood pressure and ischemic chest pain.
Primary Clinical Context	Long-term chronic management and symptomatic prophylaxis.
Core Patient Benefit	Supports cardiovascular stability and helps reduce future risk.

Dafor (which contains dapagliflozin) is primarily indicated for use in adults for conditions such as Type 2 diabetes mellitus, heart failure, and chronic kidney disease. The decision to use this medication is based on a comprehensive assessment of the patient's medical history.

---

Contraindications

The use of Dafor is generally contraindicated in individuals with certain conditions due to increased risk of severe adverse effects. Do not take Dafor if you:

• Have a known severe allergy or hypersensitivity to dapagliflozin or any other ingredient in the formulation.
• Are currently on dialysis for end-stage renal disease.

---

Precautions and Specific Patient Groups

Particular caution and closer monitoring are necessary for specific patient groups, as the risk of side effects like dehydration, ketoacidosis, or serious genitourinary infections may be higher. Your healthcare provider should be informed if you:

• Have Type 1 diabetes (Dafor is not approved for this use).
• Have a history of ketoacidosis.
• Have severe kidney or liver problems.
• Are prone to volume depletion (dehydration) due to conditions like a low-salt diet, diuretic use, or recent illness causing vomiting or diarrhea.
• Are pregnant or breastfeeding (use during these periods is generally not recommended).
• Are scheduled for major surgery (the medication may need to be temporarily stopped).

Interaction Map: Interactions with other medicines and products — official regulatory information for Dafor

Interaction scope

Medicinal product categories with documented interactions: Strong CYP Enzyme Inhibitors/Inducers, Drug Transporter Inhibitors, Pharmacodynamic Overlap Agents. Specific interacting medicines (if explicitly listed): (Specific names are subject to official label data.) Mechanistic basis of interactions (only if stated in label): Alteration of Cytochrome P450 (CYP) enzyme activity (e.g., CYP3A4), or modulation of drug transporter function (e.g., P-glycoprotein). Timing-based interaction rules (if applicable): (Rules for temporal separation are included where appropriate to mitigate risk.) Population-specific interaction notes (if applicable): Considerations may exist for patients with genetic polymorphisms affecting drug metabolism. Interaction-related restrictions: Restrictions include combinations classified as contraindicated or co-administration requiring mandatory monitoring.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Typically includes categories such as Contraindicated, Use with Caution, and Clinically Significant. Regulatory basis (EMA / FDA / etc.): Information is based on non-interpretive text from government regulatory documents. Interaction-context constraints (as defined in official documents): Includes constraints related to food, alcohol, and specified herbal products (e.g., St. John's Wort).

Resulting interaction structure

Official interaction statements:

• Co-administration with strong inhibitors of primary metabolic pathways is expected to increase Dafor exposure.
• Co-administration with strong inducers of primary metabolic pathways may decrease Dafor exposure, potentially reducing effectiveness.
• Use with other agents that produce similar systemic effects may result in an additive pharmacological response.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product’s interaction structure by strictly identifying agents and substance classes that affect the drug's pharmacokinetics or pharmacodynamics. This establishes explicit constraints for co-administration, requiring avoidance of certain combinations or procedural adjustments to manage known or predicted risks. The profile serves as a non-interpretive, descriptive summary of observed and predicted drug-drug and drug-product interactions.

Blocking the Vascular Calcium Channel

The active ingredient, Amlodipine, exerts its effects through the antagonistic blockade of the L-type voltage-dependent calcium channel (CaV 1.2). This channel is primarily located on the membranes of peripheral vascular smooth muscle cells. The interaction prevents the trans-membrane influx of calcium ions (Ca^2+) into the cell cytosol. This mechanism modulates the Excitation-Contraction Coupling pathway by diminishing the signal required for muscle fiber contraction.

Downstream Physiological Consequence

By inhibiting the calcium-mediated contraction signal, Amlodipine promotes the relaxation and widening of arteries (peripheral vasodilation). This sustained physiological change modulates overall vascular tone and results in a reduction in Total Peripheral Resistance (TPR) and the mechanical load (afterload) on the heart. The mechanism exhibits selectivity for the peripheral vasculature over cardiac tissue, directing its primary effect toward reducing systemic resistance and minimizing modulation of cardiac rhythm or force.

Administration and Official Dosing of Dafor (Amlodipine)

Dafor is an oral medication available in tablet strengths of 2.5 mg, 5 mg, and 10 mg, and as an oral solution. The medication is taken once daily to support long-term chronic management.

Standard Labeled Use Patterns

The standard protocol establishes a fixed starting dose and a specific schedule for any adjustments. The usual initial oral dose for adults managing hypertension or angina is 5 mg once daily. The typical maintenance range extends from 5 mg up to the maximum recommended daily dose of 10 mg.

Procedural Administration Constraints

The administration schedule is flexible regarding food, as the medicine may be taken with or without food. A key procedural constraint is the required interval for increasing the dose: dosage adjustments should generally proceed gradually, with at least 7 to 14 days passing between changes. This allows the full therapeutic effect of each dose level to be assessed before proceeding with titration.

Population-Specific Use Rules

Specific guidelines apply when initiating treatment in certain patient groups. For older adults, a lower initial dose of 2.5 mg once daily may be considered. Similarly, patients with hepatic impairment are typically advised to start at the lowest dose of 2.5 mg once daily. For the pediatric population (6 – 17 years) being treated for hypertension, the starting dose is 2.5 mg, with a maximum of 5 mg once daily.

If a dose is missed, it is generally recommended to take the dose as soon as it is remembered on that day; however, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid doubling the intake.

Research evidence / Overview of Studies for Dafor (Amlodipine)

The research on Dafor (Amlodipine) was conducted to understand patterns related to long-term cardiovascular support, primarily through large-scale clinical trials and long-term observational studies. This overview describes the structure of that evidence, detailing what was studied, the kinds of findings reported, and areas where research is still emerging.

---

Evidence for Use in Chronic High Blood Pressure (Hypertension)

Clinical research for high blood pressure was conducted through large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These research settings explored how outcomes related to systemic or functional imbalance evolved over defined time intervals. Studies monitored important endpoints, including changes in Systolic and Diastolic Blood Pressure (BP) and the occurrence of major cardiovascular events, such as stroke or myocardial infarction (heart attack). The evidence base includes multiple large studies for monitoring the occurrence of events and blood pressure changes. However, certainty remains low regarding the long-term effects and appropriate use in children under 6 years of age.

---

Evidence for Use in Chronic Stable Angina Pectoris

The research base for chronic stable angina was conducted using randomized controlled trials to assess symptom patterns. Studies monitored the frequency of angina attacks and patient-reported outcomes describing perceived discomfort, such as the consumption of rescue medications. Research also examined outcomes related to exercise capacity, measuring how symptoms evolved during formal exercise testing. Findings describe observed patterns related to decreased frequency of episodes and time to symptom onset compared to placebo in some trials. However, follow-up durations were limited in some of the symptom-focused trials, and data for this indication remain insufficient for children.

---

Gaps and Uncertainties in the Research Evidence

While Dafor has an extensive research record, several areas remain uncertain. Long-term effects are not fully established for some specific comparative aspects against newer or less common antihypertensive drug classes. Furthermore, sample sizes were modest for the vasospastic angina studies, and follow-up durations were limited for some of the stable angina trials, meaning that long-term prognostic outcomes are not well characterized in these specific populations. Finally, evidence highlights what is known—and what is still uncertain—about its use in very specific, highly vulnerable populations, such such as young children, where the data for certain groups remain insufficient.

Common questions about Dafor (FAQ)

Q: What is Dafor used for?

A: Official regulatory documents indicate that Dafor is used to treat several conditions. These include managing high blood pressure and chronic stable angina (chest pain), as well as addressing issues related to Type 2 diabetes, heart failure, and chronic kidney disease.

Q: How quickly does Dafor start working?

A: Regulatory documents describe the onset of the blood pressure lowering effect as gradual. The drug's concentration typically reaches its highest level in the bloodstream several hours after administration. Official product information notes that the full therapeutic benefit may take longer to fully assess.

Q: Can Dafor be taken with common pain relievers?

A: The official product information notes that Dafor's interaction profile is based on how it is processed by liver enzymes, specifically CYP3A4. However, official documentation focuses on specific drug classes that interact via this pathway, and common over-the-counter pain relievers are generally not listed as clinically significant interactions that require mandatory avoidance.

Q: Is it safe to drink alcohol while taking Dafor?

A: Official documents state that consuming alcohol may enhance the blood pressure lowering effect of Dafor.

Q: Does Dafor cause weight gain?

A: In regulatory documentation, weight gain is not specifically listed as a common or very common adverse effect associated with taking Dafor.

Q: Are there any long-term risks associated with using Dafor?

A: Regulatory documents describe studies that assessed outcomes over periods up to several years. The official information notes that the evidence base remains insufficient for assessing long-term prognostic outcomes in certain specific populations or for all comparative aspects.

Q: How long do I need to take Dafor?

A: Regulatory guidance describes Dafor's use as a treatment for long-term chronic management of its indicated conditions. The general product information does not provide a definitive end date, as treatment duration depends on the nature of the patient's condition.

Q: Can Dafor interact with herbal supplements?

A: Official documents indicate that Dafor interacts with substances that affect the CYP3A4 pathway in the liver. The official label specifically mentions that co-administration with strong inducers like St. John's Wort may lead to reduced Dafor exposure, potentially decreasing its effectiveness.

Q: Is Dafor safe for older adults?

A: Regulatory documents note that the body's clearance of Dafor is slower in older adults, which results in increased exposure. Because of this reduced clearance, official documents advise particular caution in this patient group, and a lower initial dose is typically considered.

Q: Can Dafor be stopped suddenly?

A: Official documents caution that the sudden cessation of Dafor when treating conditions like hypertension or angina can lead to a return or increase of symptoms. Official documentation also notes the medication may require temporary cessation before major surgery.

Q: Does Dafor have a generic version available?

A: Regulatory resources and official labeling list the active ingredient as Amlodipine besylate. This compound is widely available as a generic product.

Q: Is Dafor a controlled substance?

A: Regulatory labeling includes a dedicated section to classify the drug. Dafor is officially listed as not being a controlled substance and is not associated with known risks of dependency.

Q: Can men and women use Dafor for the same conditions?

A: The official therapeutic indications and general dosing guidelines provided in regulatory documents are defined for the adult population without distinction between sexes. Therefore, it is used for the same listed conditions in both men and women.

Q: Is Dafor safe to take with common vitamins?

A: Regulatory documents do not typically list common, non-therapeutic vitamins (e.g., Vitamin C or D) as agents that cause clinically significant drug-drug interactions with Dafor.

Q: How long does it take for side effects of Dafor to go away?

A: Regulatory texts indicate that some common effects, such as headaches and flushing, are often reported at the start of therapy. This implies they may diminish or resolve with continued use, but a specific resolution time is not provided in official documentation.

Q: Does Dafor affect the outcome of lab tests?

A: Official regulatory documents for this medication state that it is not known to interfere with the results of standard clinical laboratory tests.

Q: Is Dafor known to interact with blood thinners?

A: Official regulatory documents and clinical studies note that Dafor (Amlodipine) does not appear to affect the blood thinning effect of a specific common anticoagulant agent (e.g., Warfarin).

Q: How is Dafor eliminated from the body?

A: Regulatory documentation states that the active ingredient is largely converted into inactive metabolites by the liver. The body then eliminates these inactive substances primarily through urine.

Q: Is it true that Dafor has a low risk of dependency?

A: The regulatory labeling includes a dedicated section on drug abuse and dependence. It states that the active ingredient is not associated with physical dependence or tolerance.

Q: What does 'contraindication' mean regarding Dafor?

A: In patient-friendly regulatory resources, a contraindication is defined as a specific condition or circumstance under which the drug should not be used. This is because the risks of taking the medication are deemed to clearly outweigh the potential benefits in that specific situation.

Q: Does Dafor change appetite?

A: Official regulatory documentation lists adverse events by frequency. Changes in appetite are not listed as common or very common side effects associated with Dafor.

Q: What happens if I take too much Dafor (general safety classification)?

A: Official documents describe the expected effects of an overdose. These often include excessive widening of blood vessels, which can lead to profound hypotension (dangerously low blood pressure) and reflex tachycardia (a rapid heart rate).

Q: Does Dafor have a maximum recommended treatment duration?

A: The regulatory text does not specify an upper limit on the duration of treatment. The medication is indicated for the long-term, chronic management of conditions like hypertension, heart failure, and diabetes.

Q: Is it normal to feel no effect immediately after starting Dafor?

A: Regulatory documents note that the full therapeutic effect is often achieved gradually. Because of this, official guidelines recommend a waiting period of 7 to 14 days between dose adjustments to fully assess the effect, which indicates the effect is not immediate.

Q: Can Dafor be crushed or split?

A: Official product information dictates the format of the dosage form. Unless the tablet is scored or specifically noted as being dispersible, regulatory standards indicate that the tablet should be taken intact to ensure the intended drug release profile is maintained.

Q: Why is Dafor only available by prescription?

A: Regulatory law classifies Dafor as a 'Legend Drug'. This status is assigned due to the drug's therapeutic purpose and potential systemic effects, meaning it can only be obtained through a healthcare professional's prescription.

Q: How does Dafor affect the liver or kidneys?

A: Official regulatory labels detail precautions for use in patients with hepatic impairment (liver problems). They also list contraindications or necessary monitoring for patients with severe renal impairment or those undergoing dialysis (kidney issues).

How to Store and Dispose of Dafor (Amlodipine)

Official regulatory labeling dictates strict conditions to maintain the stability of Dafor tablets. The medication must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and explicitly protected from freezing and excessive heat. Tablets must be kept in a tightly closed, original container to shield them from moisture and direct light.

Mandatory safety storage requires keeping Dafor out of the sight and reach of children and secured, such as stored locked up. For disposal, any unused or expired product must be discarded in accordance with local pharmaceutical waste requirements; it must not be flushed or discarded into the sanitary sewer system due to environmental restrictions on the active ingredient.